Novartis: New hope for HR+/HER2- Advanced Breast Cancer Patients
Novartis Pharma SAE (Novartis Egypt) has announced final overall survival (OS) results for the Phase III MONALEESA-2 study. The study ...
Novartis Pharma SAE (Novartis Egypt) has announced final overall survival (OS) results for the Phase III MONALEESA-2 study. The study ...
Novartis Pharma S.A.E (Novartis Egypt), announced the launch of the newly approved treatment for PIK3CA-mutated HR+ve advanced Breast Cancer. The ...
© 2024 Egyptian Gazette - Admined by Digital Transformation Management.
© 2024 Egyptian Gazette - Admined by Digital Transformation Management.